Re: I just keep coming back to the same question.
Post# of 15624
A--- they don't have adequate patent protection on their products so they are limited to what they want to share with potential investors... no investors going to pony up cash if you don't want have break through progress on the table..
or
B--- Their science is not sound yet? hence, they have not perfected the smell of the cream.. Hence, they abandoned the OTC route.. Hence, they are putting the cream back on the shelf for at least 2 more years..
Hence, they realized that they will not able to access to non-toxic fund if they don't put a product on the shelf or show more promising route to revenue. .. Now, they are changing direction and try to rush the tablet out the door or looks like they have more urgency to get the tablet moving..
If the tablet trail does go according to their plan of ending July, that's a month reduction from their original 4 months projection (per shareholder letter).
we'll see if they can follow through on their plan..
3 months tablet trail..
If successfully, they are going to seek approval and produce/export their tablet..
The way they handled the RS, the market are NOT confident on their plan.
As much as I want to avg. down, it's not easy to throw more money at this stage. also, I've very little dry powder left now..